The ongoing goals of CORE A will be: 1) to provide generalized administrative support, 2) to insure efficient and appropriate usage of core services by the individual projects, 3) to coordinate and organize monthly research meetings of the program investigators, 4) to provide mechanisms of conflict resolution and potential rebudgeting issues, 5) to provide constructive review of the research through Internal and External advisory committees, 6) to provide budgetary services, such as tracking the expenditures of the program and providing monthly reports to the investigators, 7) to provide an objective quality assurance program that will monitor the clinical trials, and 8) to provide assistance and coordination with regulatory agencies within the Penn campus and with the FDA and R.A.C. The administrative functions (Goals 1-5) will be accomplished using a structure in which the Core Leader, Dr. Albelda, is advised by an Executive Committee of Project and Core Leaders with input from Internal and External Advisory Committees. He will be assisted by an administrative assistant, Ms. Pelzer. The budgetary goal (Goal 6) will be performed by Ms. Lavinia Pritchett. She will be responsible for facilitating communication and will have budgetary responsibility with oversight from Dr. Albelda. To provide an objective quality assurance program that will monitor the clinical trials, and to provide assistance and coordination with regulatory agencies within the PENN campus and with the FDA and R.A.C. (Goals 7 and 8), the Core will continue to utilize Penn's Office of Human Research and a regulatory consultant, Mr. Phillip Cross.
Malignant mesothelioma is currently considered incurable. New approaches are needed. This Core provides the administrative infrastructure to support the clinical and preclinical studies of the Program Project.
|Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47|
|Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNÎ± Combined with Chemotherapy. Clin Cancer Res 22:3791-800|
|O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60|
|Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90|
|Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430|
|Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51|
|Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res 3:815-26|
|Frigault, Matthew J; Lee, Jihyun; Basil, Maria Ciocca et al. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356-67|
|Lo, Albert; Wang, Liang-Chuan S; Scholler, John et al. (2015) Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 75:2800-10|
|Liu, Xiaojun; Jiang, Shuguang; Fang, Chongyun et al. (2015) Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 75:3596-607|
Showing the most recent 10 out of 82 publications